PR Newswire Clinical TrialsOriginal article
El pertuzumab de Biocon se convierte en el primer biosimilar en obtener una opinión positiva del CHMP de la EMA bajo el nuevo enfoque clínico adaptado
Regulatorypositivepertuzumab biosimilarPositive
AI Analysis
Summary
Biocon Biologics received a positive CHMP opinion from the European Medicines Agency for its pertuzumab biosimilar, marking the first biosimilar to achieve this under the EMA's new adapted clinical approach.
Outcome Details
CHMP positive opinion for pertuzumab biosimilar under adapted clinical approach
Importance:7/10
Sentiment:
0.85
biosimilarEMA approvalCHMP positive opinionregulatory milestoneoncology
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 22, 2026 11:56 AM